CED and Personalized Medicine: A Perfect Match?
This article was originally published in RPM Report
Medicare is hoping to refine the coverage with evidence development a better process to make it a better tool for driven more cost effective health care. Personalized medicine advocates are trying to drive better adoption of genomic-guided treatment strategies. Is this a match made in heaven?
You may also be interested in...
FDA has put a lot of thought into preparing for the drug/diagnostic companion products that presage the era of personalized medicine; but the lure of fewer controls and less development costs is tugging some of the effort off-shore. FDA is also scaring off small companies from genomic test projects and their VC investors. Is this really an opportunity that is slipping away from the US or just an opportunity only for some participants?
US FDA’s workshop to discuss new ideas to assess the impact of the opioid REMS comes after the industry collaboration behind the REMS has deemed the task essentially impossible.
Whether CME for pain management has the intended impact on prescribing is likely focus of new ‘suite of studies’ intended to assess the opioid REMS program. The challenges for FDA include teasing out the impact of the risk management program amid all the other public health efforts on opioids.